ArticleChemical biology & drug design2015
Cost-effectiveness and pricing of antibacterial drugs.
Article in Chemical biology & drug design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cost-effectiveness analysis of linezolid versus vancomycin in the treatment of adult hospital-acquired and ventilator-associated methicillin-resistant staphylococcus Aureus Pneumonia (a systematic review).Cost effectiveness and resource allocation : C/E · 2026Review
- Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- From 60 Causes to 10 Solutions Against Antibiotics Shortages in Sweden: Platinea's Approach to Developing Policy Interventions.Antibiotics (Basel, Switzerland) · 2025Article
- Macro- and micro-influencers of antimicrobial costs…What do stewardship programs need to know?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Antimicrobial Agents Based on Metal Complexes: Present Situation and Future Prospects.International journal of biomaterials · 2022Review
- Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy.Health economics review · 2021Article
- Choosing Optimal Antibiotics for the Treatment of Patients Infected WithFrontiers in pharmacology · 2021Article
- How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance.Infection and drug resistance · 2020Review
- Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection.Nature microbiology · 2019Article
- Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).Antimicrobial resistance and infection control · 2019Article
- Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials.Bioorganic & medicinal chemistry letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing resistance to antibacterial agents has increased the need for the development of new drugs to treat bacterial infections. Given increasing pressure on limited health budgets, it is important to study the cost-effectiveness of these drugs, as well as their safety and efficacy, to find out whether or not they provide value for money and should be reimbursed. In this article, we systematically reviewed 38 cost-effectiveness analyses of new antibacterial agents. Most studies showed the new antibacterial drugs were cost-effective compared to older generation drugs. Drug pricing is a complicated process, involving different stakeholders, and has a large influence on cost-effectiveness. Value-based pricing is a method to determine the price of a drug at which it can be cost-effective. It is currently unclear what the influence of value-based pricing will be on the prices of new antibacterial agents, but an important factor will be the definition of 'value', which as well as the impact of the drug on patient health might also include other factors such as wider social impact and the health impact of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.